Hypromellose, Unspecified & SUCROSE Excipient Use in Tablet Delayed Release Dosage Forms

Hypromellose, Unspecified

FDA Inactive Ingredient Details, DESCRIPTION

Suppliers

10 Listed Products, 1 Pfanstiehl, 1 Actylis, 1 DKSH, 1 Gangwal Chemicals, 6 Seppic

REGULATORY FILINGS

6 Suppliers, 6 USDMF, 4 NDC API

SOLUTIONS BY APPLICATIONS

9 Coating Systems & Additives, 3 Taste Masking, 2 Coloring Agents, 2 Thickeners and Stabilizers

ANALYTICAL SOLUTION(s)

3 Other Ref. Standards

3 Other Ref. Standards

FINISHED FORMULATIONS

572 ORAL, 135 TABLET, 69 CAPSULE, EXTENDED RELEASE, 63 SOLUTION, 56 FOR SUSPENSION, 50 CAPSULE, 45 SYRUP, 44 CAPSULE, DELAYED REL PELLETS, 39 SUSPENSION, 17 TABLET, EXTENDED RELEASE, 12 CAPSULE, DELAYED RELEASE, 11 INJECTABLE, 11 POWDER, 9 FOR SOLUTION, 9 SUSPENSION, EXTENDED RELEASE, 8 INJECTION, 8 TABLET, CHEWABLE, 7 INTRAVENOUS, 7 ORAL-28, 6 ORAL-21, 6 TABLET, DELAYED RELEASE, 5 TABLET, ORALLY DISINTEGRATING, 4 GRANULE, 4 VIAL, 3 ELIXIR, 3 SUBCUTANEOUS, 2 CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS, 2 CONCENTRATE, 2 FOR SUSPENSION, EXTENDED RELEASE, 2 SUSPENSION/DROPS, 2 TRANSMUCOSAL, 2 TROCHE/LOZENGE, 1 EMULSION, 1 INJECTABLE, LIPOSOMAL, 1 INTRAVENOUS, SUBCUTANEOUS, 1 IV (INFUSION), 1 NASAL, 1 POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER, 1 SINGLE-USE, 1 SPRAY, METERED, 1 SUBCUTANEOUS LYOPHILIZED POWER, 1 SYRINGE